Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Adial Pharmaceuticals, Inc.Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee has granted a new employee stock option to purchase 155,446 shares of common stock as an inducement to such person becoming an employee of the Company.
- Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family ConferenceBright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown.
- Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
- Robbins LLPRobbins LLP is Investigating Allegations that Ardelyx, Inc. Misled Investors Regarding the True State of the Company's Commercial Performance and Growth Prospects for its Two Core Drug ProductsShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Ardelyx, Inc. develops and commercializes medicines, including ISBRELA for the treatment of irritable bowel syndrome with constipation and XPHOZAH for reducing...
- The Rosen Law Firm PAAARDVARK DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 13 Deadline in Securities Class Action - AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the...
- Oculis Announces Resignation of Lionel Carnot from Board of DirectorsOculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017.
- MicrosoftHow AI could help scientists find viruses to fight drug-resistant infectionsCompanies: MicrosoftThe post How AI could help scientists find viruses to fight drug-resistant infections appeared first on Source.
- DEA SCHEDULE I PROPOSAL WOULD CRIMINALIZE COMPOUND WITH BREAKTHROUGH THERAPY STATUS FOR POSTPARTUM DEPRESSIONNow SSDP is mobilizing researchers, patients, students, and the public to fight the proposed scheduling of five tryptamines. Submit a public comment to the DEA by October 23 using SSDP’s easy-to-use public comment tool. WASHINGTON, D.C. – September 30, 2026 — A psychedelic drug granted Breakthrough Therapy designation by the U.S. Food and Drug […]
- Liquidia Provides Update on Hatch-Waxman Litigation Tied to ‘327 PatentLiquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding the litigation filed by United Therapeutics Corporation (UTHR) in the U.S. District Court for the District of Delaware (the Court) under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 (‘327 patent) and the Company’s lead product, YUTREPIA® (treprostinil) inhalation powder.
- NYU Langone Health SystemSugar Amplifies Damage Done to Gut Health by AntibioticsEating sweets while taking antibiotics may worsen the harm done by the drugs to the normal community of bacteria in the gut, a new study found. The work centers on the intestinal microbiome, which harbors bacterial species that co-evolved with...
- Ontario impulsa la innovación en ciencias de la vida en las instalaciones de Piramal Pharma en AuroraPiramal Pharma Solutions ("PPS"), una organización líder mundial de desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd....
- Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- to high-risk prostate cancer at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2026.